Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical announced positive results from the WSD4000 Home User study, which showed improvements in sexual function among women with sexual dysfunction. The study’s success suggests a significant market opportunity for WSD4000, which aims to address the underserved female sexual health market with a novel topical treatment. The company plans to proceed with an Early Feasibility Study to refine its approach and enhance product efficacy, potentially positioning itself strongly within the sexual health industry.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and commercialization of innovative sexual health products. Their core strengths lie in research and development of topically delivered gel formulations, with key products including Eroxon®, a treatment for erectile dysfunction, and WSD4000, a treatment for female sexual dysfunction. The company has partnerships in major markets, addressing significant unmet needs in sexual health.
YTD Price Performance: -4.03%
Average Trading Volume: 660,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £92.25M
For a thorough assessment of FUM stock, go to TipRanks’ Stock Analysis page.
